Corporate Finance
Eli Lilly’s Cancer Treatment Investment: The POINT Biopharma Deal
Download PDF Introduction On October 3rd, pharmaceutical giant Eli Lilly and Company [LLY:NYSE] announced its plans to strengthen its collection of cancer drugs through the acquisition of POINT Biopharma [PNT:NASDAQ] for $1.4bn, representing a premium of almost 90%. The firm’s purchase of POINT, a clinical-stage radiopharmaceutical company with a focus Read more…